Publication: Autologous bone-marrow mononuclear stem cell therapy in patients with stroke: A meta-analysis of comparative studies
Issued Date
2020-09-29
Resource Type
ISSN
1475925X
Other identifier(s)
2-s2.0-85092401440
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BioMedical Engineering Online. Vol.19, No.1 (2020)
Suggested Citation
Sorayouth Chumnanvej, Siriluk Chumnanvej Autologous bone-marrow mononuclear stem cell therapy in patients with stroke: A meta-analysis of comparative studies. BioMedical Engineering Online. Vol.19, No.1 (2020). doi:10.1186/s12938-020-00819-7 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/59966
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Autologous bone-marrow mononuclear stem cell therapy in patients with stroke: A meta-analysis of comparative studies
Author(s)
Abstract
© 2020 The Author(s). Background: There is a need to promote recovery after stroke with novel therapeutic interventions. Of them, bone-marrow mononuclear cell (BM-MNC) therapy offers promising outcomes in preclinical and clinical models. Aims: To investigate the efficacy and safety of BM-MNCs versus traditional medical care of stroke patients. Summary of review: A meta-analysis was conducted involving controlled prospective studies and randomized clinical trials (RCTs) which investigated the changes in the scores of neurological functions (the National Institutes of Health Stroke Scale [NIHSS]), the indices of functional recovery (the Barthel Index [BI] and the modified Rankin scale [mRS]) at 3 and 6 month post-transplantation. A total of nine studies (five RCTs) recruited 469 stroke patients (65.5% males, 49.25% received the intervention). There were no significant differences in NIHSS, BI, or mRS scores after 3 months of follow-up. However, the BI indices of BM-MNCs-receiving patients improved significantly after 6 months (standardized mean difference = 1.17, 95% confidence interval, 0.23 to 2.10, P = 0.01) as compared to traditional treatment. The risk of mortality and adverse events and the proportion of patients with favorable outcomes (mRS ≤ 3) were similar in both groups. Conclusion: Both the BM-MNCs and medical stroke treatment have similar outcomes in terms of safety and short-term efficacy, while the effect of therapy is significant only after 6 months. More well-designed, large sized RCTs are needed to confirm the efficacy of stem cell therapy over long periods of follow-up.